APAC Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Asia-Pacific lung cancer diagnostics market is projected to register a substantial CAGR of 16.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation:

Asia-Pacific Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific lung cancer diagnostics market are:

Rise in prevalence and incidence of lung cancer

Increase in awareness about the lung cancer diagnostics

Market Players:

Some of the major players operating in the Asia-Pacific lung cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific Inc.

Abbott

Quest Diagnostics Incorporated

Amoy Diagnostics Co., Ltd.

Bio-Rad Laboratories, Inc.

Biocartis

Boditech Med Inc.

Danaher

Vela Diagnostics

DiaSorin S.p.A.

Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)

LalPathLabs.com

MedGenome

Myriad Genetics, Inc.

NeoGenomics Laboratories

NanoString

Nanoentek

PerkinElmer Inc.

PlexBio

QIAGEN

Siemens Healthcare GmbH

1 INTRODUCTION 52

1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET 52
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 54

2 MARKET SEGMENTATION 57

2.1 MARKETS COVERED 57
2.2 GEOGRAPHICAL SCOPE 58
2.3 YEARS CONSIDERED FOR THE STUDY 59
2.4 CURRENCY AND PRICING 59
2.5 DBMR TRIPOD DATA VALIDATION MODEL 60
2.6 MULTIVARIATE MODELLING 63
2.7 PRODUCT TYPE LIFELINE CURVE 63
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 MARKET TESTING TYPE COVERAGE GRID 68
2.11 VENDOR SHARE ANALYSIS 69
2.12 SECONDARY SOURCES 70
2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 74

4.1 PORTER'S FIVE FORCES 75
4.2 PESTEL ANALYSIS 76
4.3 INDUSTRY INSIGHTS 77

5 EPIDERMIOLOGY 78

6 REGULATIONS 79

7 MARKET OVERVIEW 82

7.1 DRIVERS 84
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 84
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 85
- 7.1.3 INCREASING CASES OF LUNG CANCER 87
- 7.1.4 RISE IN PRODUCT APPROVALS 87
7.2 RESTRAINTS 89
- 7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 89
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 89
7.3 OPPORTUNITIES 91
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 91
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 91
- 7.3.3 RISING AWARENESS OF LUNG CANCER 92
7.4 CHALLENGES 93
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 93
- 7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
- 7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94

8 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 95

8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
- 8.2.1 IMAGING INSTRUMENTS 100
  - 8.2.1.1 CT SYSTEMS 100
  - 8.2.1.2 ULTRASOUND SYSTEMS 100
  - 8.2.1.3 MRI SYSTEMS 100
  - 8.2.1.4 OTHERS 100
- 8.2.2 BIOPSY INSTRUMENTS 101
  - 8.2.2.1 NEEDLE BIOPSY 101
  - 8.2.2.2 ENDOSCOPIC BIOPSY 101
  - 8.2.2.3 CORE BIOPSY 101
  - 8.2.2.4 OTHERS 101
- 8.2.3 PATHOLOGY-BASED INSTRUMENTS 102
  - 8.2.3.1 SLIDE STAINING SYSTEMS 102
  - 8.2.3.2 TISSUE PROCESSING SYSTEMS 102
  - 8.2.3.3 CELL PROCESSORS 102
  - 8.2.3.4 PCR INSTRUMENTS 102
  - 8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 102
8.3 CONSUMABLES AND ACCESSORIES 103
- 8.3.1 KITS 104
  - 8.3.1.1 DNA POLYMERASE KITS 104
  - 8.3.1.2 NUCLEIC ACID ISOLATION KITS 104
  - 8.3.1.3 PCR KITS 104
  - 8.3.1.4 OTHERS 104
- 8.3.2 REAGENTS 105
  - 8.3.2.1 ASSAYS 105
  - 8.3.2.2 BUFFERS 105
  - 8.3.2.3 PRIMERS 105
  - 8.3.2.4 OTHERS 105
- 8.3.3 PROBES 106
- 8.3.4 OTHER CONSUMABLES 106

9 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 107

9.1 OVERVIEW 108
9.2 IMAGING TEST 111
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 112
- 9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 112
- 9.2.3 CHEST X-RAY 112
- 9.2.4 BONE SCAN 112
- 9.2.5 MRI 112
- 9.2.6 OTHERS 112
9.3 BIOMARKERS TEST 113
- 9.3.1 EGFR MUTATION TEST 114
- 9.3.2 KRAS MUTATION TEST 114
- 9.3.3 ALK TEST 114
- 9.3.4 HER2 TEST 114
- 9.3.5 OTHERS 115
9.4 BIOPSY 115
- 9.4.1 NEEDLE BIOPSY 116
- 9.4.2 BRONCHOSCOPY BIOPSY 116
- 9.4.3 CORE BIOPSY 116
- 9.4.4 OTHERS 116
9.5 BLOOD TEST 116
- 9.5.1 COMPLETE BLOOD COUNT (CBC) 117
- 9.5.2 BLOOD CHEMISTRY TESTS 117
- 9.5.3 OTHERS 117
9.6 OTHERS 118

10 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119

10.1 OVERVIEW 120
10.2 NON-SMALL CELL LUNG CANCER 123
10.3 SMALL CELL LUNG CANCER 124

11 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY END USER 125

11.1 OVERVIEW 126
11.2 HOSPITAL 129
11.3 ASSOCIATED LABS 129
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 130
11.5 DIAGNOSTIC IMAGING CENTERS 131
11.6 CANCER RESEARCH INSTITUTES 131
11.7 OTHERS 132

12 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 133

12.1 OVERVIEW 134
12.2 DIRECT TENDER 137
12.3 RETAIL SALES 138

13 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, BY REGION 139

13.1 ASIA-PACIFIC 140
- 13.1.1 CHINA 150
- 13.1.2 JAPAN 155
- 13.1.3 SOUTH KOREA 160
- 13.1.4 AUSTRALIA 165
- 13.1.5 INDIA 170
- 13.1.6 SINGAPORE 175
- 13.1.7 INDONESIA 180
- 13.1.8 PHILIPPINES 185
- 13.1.9 VIETNAM 190
- 13.1.10 MALAYSIA 195
- 13.1.11 THAILAND 200
- 13.1.12 NEW ZEALAND 205
- 13.1.13 TAIWAN 210
- 13.1.14 REST OF ASIA-PACIFIC 215

14 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 216

14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 216

15 SWOT ANALYSIS 217

16 COMPANY PROFILE 218

16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 218
- 16.1.1 COMPANY SNAPSHOT 218
- 16.1.2 REVENUE ANALYSIS 218
- 16.1.3 COMPANY SHARE ANALYSIS 219
- 16.1.4 PRODUCT PORTFOLIO 219
- 16.1.5 RECENT DEVELOPMENTS 219
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 220
- 16.2.1 COMPANY SNAPSHOT 220
- 16.2.2 REVENUE ANALYSIS 220
- 16.2.3 COMPANY SHARE ANALYSIS 221
- 16.2.4 PRODUCT PORTFOLIO 221
- 16.2.5 RECENT DEVELOPMENTS 221
16.3 ABBOTT (2022) 222
- 16.3.1 COMPANY SNAPSHOT 222
- 16.3.2 REVENUE ANALYSIS 222
- 16.3.3 COMPANY SHARE ANALYSIS 223
- 16.3.4 PRODUCT PORTFOLIO 223
- 16.3.5 RECENT DEVELOPMENTS 223
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 224
- 16.4.1 COMPANY SNAPSHOT 224
- 16.4.2 REVENUE ANALYSIS 224
- 16.4.3 COMPANY SHARE ANALYSIS 225
- 16.4.4 PRODUCT PORTFOLIO 225
- 16.4.5 RECENT DEVELOPMENTS 227
16.5 BIODESIX (2022) 228
- 16.5.1 COMPANY PROFILE 228
- 16.5.2 REVENUE ANALYSIS 228
- 16.5.3 COMPANY SHARE ANALYSIS 229
- 16.5.4 PRODUCT PORTFOLIO 229
- 16.5.5 RECENT DEVELOPMENTS 229
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 230
- 16.6.1 COMPANY SNAPSHOT 230
- 16.6.2 PRODUCT PORTFOLIO 230
- 16.6.3 RECENT DEVELOPMENTS 230
16.7 BIO-RAD LABORATORIES, INC. (2022) 231
- 16.7.1 COMPANY SNAPSHOT 231
- 16.7.2 REVENUE ANALYSIS 231
- 16.7.3 PRODUCT PORTFOLIO 232
- 16.7.4 RECENT DEVELOPMENTS 232
16.8 BIOCARTIS (2022) 233
- 16.8.1 COMPANY SNAPSHOT 233
- 16.8.2 REVENUE ANALYSIS 233
- 16.8.3 PRODUCT PORTFOLIO 234
- 16.8.4 RECENT DEVELOPMENTS 234
16.9 BODITECH MED INC. 235
- 16.9.1 COMPANY PROFILE 235
- 16.9.2 PRODUCT PORTFOLIO 235
- 16.9.3 RECENT DEVELOPMENTS 235
16.10 DANAHER (2022) 236
- 16.10.1 COMPANY SNAPSHOT 236
- 16.10.2 REVENUE ANALYSIS 236
- 16.10.3 PRODUCT PORTFOLIO 237
- 16.10.4 RECENT DEVELOPMENTS 237
16.11 DIASORIN S.P.A. (2022) 238
- 16.11.1 COMPANY SNAPSHOT 238
- 16.11.2 REVENUE ANALYSIS 238
- 16.11.3 PRODUCT PORTFOLIO 239
- 16.11.4 RECENT DEVELOPMENTS 239
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 240
- 16.12.1 COMPANY SNAPSHOT 240
- 16.12.2 REVENUE ANALYSIS 240
- 16.12.3 PRODUCT PORTFOLIO 241
- 16.12.4 RECENT DEVELOPMENTS 241
16.13 20/20 GENE SYSTEMS 242
- 16.13.1 COMPANY PROFILE 242
- 16.13.2 PRODUCT PORTFOLIO 242
- 16.13.3 RECENT DEVELOPMENTS 242
16.14 GUARDANT HEALTH INC. 243
- 16.14.1 COMPANY PROFILE 243
- 16.14.2 PRODUCT PORTFOLIO 243
- 16.14.3 RECENT DEVELOPMENTS 243
16.15 INIVATA LTD. 244
- 16.15.1 COMPANY PROFILE 244
- 16.15.2 PRODUCT PORTFOLIO 244
- 16.15.3 RECENT DEVELOPMENTS 244
16.16 LALPATHLABS.COM (2022) 245
- 16.16.1 COMPANY SNAPSHOT 245
- 16.16.2 REVENUE ANALYSIS 245
- 16.16.3 PRODUCT PORTFOLIO 246
- 16.16.4 RECENT DEVELOPMENTS 247
16.17 LUNGLIFE AI, INC. (2022) 248
- 16.17.1 COMPANY SNAPSHOT 248
- 16.17.2 PRODUCT PORTFOLIO 248
- 16.17.3 RECENT DEVELOPMENTS 248
16.18 MEDGENOME 249
- 16.18.1 COMPANY SNAPSHOT 249
- 16.18.2 PRODUCT PORTFOLIO 249
- 16.18.3 RECENT DEVELOPMENTS 250
16.19 MYRIAD GENETICS, INC. 251
- 16.19.1 COMPANY SNAPSHOT 251
- 16.19.2 PRODUCT PORTFOLIO 251
- 16.19.3 RECENT DEVELOPMENTS 251
16.20 NEOGENOMICS LABORATORIES (2022) 252
- 16.20.1 COMPANY SNAPSHOT 252
- 16.20.2 REVENUE ANALYSIS 252
- 16.20.3 PRODUCT PORTFOLIO 253
- 16.20.4 RECENT DEVELOPMENTS 253
16.21 NANOSTRING (2022) 254
- 16.21.1 COMPANY SNAPSHOT 254
- 16.21.2 REVENUE ANALYSIS 254
- 16.21.3 PRODUCT PORTFOLIO 255
- 16.21.4 RECENT DEVELOPMENTS 255
16.22 NANOENTEK 256
- 16.22.1 COMPANY PROFILE 256
- 16.22.2 PRODUCT PORTFOLIO 256
- 16.22.3 RECENT DEVELOPMENTS 256
16.23 ONCOCYTE CORPORATION 257
- 16.23.1 COMPANY PROFILE 257
- 16.23.2 SERVICE PORTFOLIO 257
- 16.23.3 RECENT DEVELOPMENTS 257
16.24 PERKINELMER INC 258
- 16.24.1 COMPANY PROFILE 258
- 16.24.2 REVENUE ANALYSIS 258
- 16.24.3 PRODUCT PORTFOLIO 259
- 16.24.4 RECENT DEVELOPMENTS 259

16.25 PLEXBIO 260
- 16.25.1 COMPANY SNAPSHOT 260
- 16.25.2 PRODUCT PORTFOLIO 260
- 16.25.3 RECENT DEVELOPMENTS 260
16.26 QIAGEN 261
- 16.26.1 COMPANY SNAPSHOT 261
- 16.26.2 REVENUE ANALYSIS 261
- 16.26.3 PRODUCT PORTFOLIO 262
- 16.26.4 RECENT DEVELOPMENTS 262
16.27 SIEMENS HEALTHCARE GMBH 263
- 16.27.1 COMPANY SNAPSHOT 263
- 16.27.2 REVENUE ANALYSIS 263
- 16.27.3 PRODUCT PORTFOLIO 264
- 16.27.4 RECENT DEVELOPMENTS 264
16.28 VERACYTE, INC. (2022) 265
- 16.28.1 COMPANY SNAPSHOT 265
- 16.28.2 REVENUE ANALYSIS 265
- 16.28.3 PRODUCT PORTFOLIO 266
- 16.28.4 RECENT DEVELOPMENTS 266
16.29 VELA DIAGNOSTICS 267
- 16.29.1 COMPANY PROFILE 267
- 16.29.2 PRODUCT PORTFOLIO 267
- 16.29.3 RECENT DEVELOPMENTS 269

17 QUESTIONNAIRE 270

18 RELATED REPORTS 273

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 31
FIGURE 2 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 34
FIGURE 3 ASIA PACIFIC LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 35
FIGURE 4 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 36
FIGURE 5 ASIA PACIFIC LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 36
FIGURE 6 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 39
FIGURE 7 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 40
FIGURE 8 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 42
FIGURE 9 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 43
FIGURE 10 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 47
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD 48
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030 48
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET 57
FIGURE 14 THE ASIA PACIFIC MORTALITY RATE DUE TO CANCER 60
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING ASIA PACIFIC CANCER RATE IN 2020 60
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 63
FIGURE 17 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 70
FIGURE 18 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 71
FIGURE 19 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 71
FIGURE 20 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 72
FIGURE 21 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 82
FIGURE 22 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 83
FIGURE 23 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 83
FIGURE 24 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 84
FIGURE 25 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 94
FIGURE 26 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 95
FIGURE 27 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 95
FIGURE 28 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 96
FIGURE 29 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022 100
FIGURE 30 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 101
FIGURE 31 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 101
FIGURE 32 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 102
FIGURE 33 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 108
FIGURE 34 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 109
FIGURE 35 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 109
FIGURE 36 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 110
FIGURE 37 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 115
FIGURE 38 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 116
FIGURE 39 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 116
FIGURE 40 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 117
FIGURE 41 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 117
FIGURE 42 ASIA PACIFIC LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 190